Strikingly, although the frequency of GM-CSF-producing CD4+ TEM cells was decreased in MG patients in general, it was especially low in the blood of newly diagnosed treatment-naïve MG patients with highly active disease compared to those with mild disease, where MG severity is assessed by the modified quantitative MG score [6] (Fig. 2c, Supplementary Fig. 2d). This evidence concerns the gene CSF2 and myasthenia gravis.